louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01959607: Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
Official title: A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Healthy Smokers Compared to Conventional Cigarettes and Nicotine Gum
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Keywords: Smoking
Nicotine absorption
Candidate modified risk tobacco product
Cigarettes
Nicotine Replacement Therapy gum (NRT gum)
Lead sponsor: Philip Morris Products S.A.
Sponsor class: INDUSTRY
First posted: 2013-10-10
Enrollment: 65
Sex: ALL
Minimum age (years): 23
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The overall goal of the study is to evaluate the pharmacokinetic (PK) profile (rate and the amount of nicotine absorbed) following a single use of the THS 2.2, a candidate Modified Risk Tobacco Product, compared to the PK profiles from a single use of a cigarette (CC) and from a single use of nicotine gum in a Japanese population.


Eligibility criteria: Inclusion Criteria:

* Subject is Japanese.
* Smoking, healthy subject as judged by the Investigator.
* Subject smokes at least 10 commercially available CCs per day (no brand restrictions) for the last 4 weeks.
* Subject does not plan to quit smoking in the next 3 months.

Exclusion Criteria:

* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
* Subject has received medication within 14 days or within 5 half-lives of a drug (whichever is longer) which has an impact on CYP2A6 activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.

Primary outcomes:
measure: Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2, CC and NRT
timeFrame: Blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0
measure: Area Under the Plasma Concentration-Time Curve From Time Zero (Pre-product Use) to Last Time Point [AUC(0-last)] Following Single Use of THS 2.2, CC and NRT
timeFrame: Blood taken 15 minutes prior to T0, 2, 4, 6, 8, 10, 15, 30, 45 minutes, 1, 2, 4, 6, 9, 12, and 24 hours after T0
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Koganeibashi Sakura Clinic, 2-11-25, Sakuracho, Koganei-shi
Study officials:
affiliation: Koganeibashi Sakura Clinic
name: Masayuki Sugimoto, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Philip Morris Products S.A.
name: Christelle Haziza, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03884088: Comparison of Subjective Balance Tests
Official title: Comparison of Sensitivity of the Subjective Balance Tests
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Balance
Posture
Keywords: Balance
Limits of Stability
Postural Sway
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2019-03-21
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: There is many subjective balance tests to evaluate static and dynamic balance. But, there is no sufficient information about which balance test is the most sensitive test to evaluate balance. Therefore, the aim of this study is to compare of sensitivity of the subjective balance tests with an objective system.

Detailed description: In the clinical setting, many balance tests are used for evaluating balance in individuals. These tests are utilized to assess both static and dynamic balance. However, sufficient research has not been conducted to decide which subjective balance test is more sensitive than the other tests. Therefore, the aim of this study is to compare of sensitivity of the subjective balance tests with an objective system.

Eligibility criteria: Inclusion Criteria:

* at least 18 years,
* To be a volunteer to participate

Exclusion Criteria:

* orthopedic problems affecting gait and stance
* visual, auditory, orientational problems that could affect study results,
* Walking with assist device
* Having a neurological disorders

Primary outcomes:
measure: Limits of Stability
timeFrame: 15 minutes
measure: Postural Sway
timeFrame: 15 minutes
Secondary outcomes:
measure: Timed up and go test
timeFrame: 15 minutes
measure: Functional reach test
timeFrame: 15 minutes
measure: One-leg stance test
timeFrame: 15 minutes
measure: Romberg test
timeFrame: 15 minutes
measure: Berg balance scale
timeFrame: 15 minutes
measure: Balance scale
timeFrame: 15 minutes
measure: Y balance test
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ozden Ozkal
Study officials:
References:
Clinical trial NCT04932707: Stretching Exercises on Hamstring Flexibility.
Official title: Effect of Adding Suboccipital Muscle Release Versus Neurodynamic Mobilization to Passive Hamstring Stretch in Subjects With Short Hamstring Syndrome.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hamstring Muscle
Flexibility
Keywords: hamstring
Stretch
Sub-occipital inhibition
Neuro-dynamic
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Batterjee Medical College
First posted: 2021-06-21
Enrollment: 117
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The hamstrings muscles are examples of muscle groups that have a tendency to shorten.

Limited flexibility has been shown to predispose a person to several musculoskeletal overuse injuries and significantly affect a person's function.

Detailed description: The objective of this study will be to compare the effect of three different methods of stretching techniques on the flexibility of hamstring muscle in subjects with short hamstring syndrome.

HYPOTHESES:

There will be no difference between sub-occipital muscle inhibition technique, neuro-dynamic slump stretch, or passive hamstring stretch on hamstring flexibility in subjects with short hamstring syndrome.

RESEARCH QUESTION:

Is there is any difference between suboccipital muscle inhibition technique, neurodynamic slump stretch, or passive hamstring stretch on hamstring flexibility in patients with short hamstring syndrome?

Eligibility criteria: Inclusion Criteria:

* undergraduate female students
* body mass index 18-25 kg/cm square.
* All subjects will be free from injury or disease expected to affect hamstring length or ability to perform the exercises.

Exclusion Criteria:

* Hamstring injury within the past year.
* Verbal report of performing regular lower extremity.
* Current Muscle stretching exercises.
* History of neck trauma (whiplash).
* History of recent fracture in any part of the body.
* History of neurological or orthopedic disorders
* Diagnosis of a herniated disk
* Low back pain in the last 6 months

Primary outcomes:
measure: knee extension angle test
timeFrame: Immediately after the procedure
measure: knee extension angle test
timeFrame: 4 weeks
Secondary outcomes:
measure: Straight leg raising test
timeFrame: Immediately after the procedure
measure: Straight leg raising test
timeFrame: 4 weeks
measure: Forward flexion test
timeFrame: Immediately after the procedure
measure: Forward flexion test
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Olfat Ibrahim Ali
state: Dokki
Study officials:
affiliation: Cairo University
name: Olfat I Ali, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03637907: Spectral Computed Tomography With Photon Counting Detector of Brain and Vessels.
Official title: Spectral Computed Tomography With Photon Counting Detector of Brain and Vessels.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tomography
Stroke
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2018-08-20
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients in the ordinary stroke workup that do both CT brain and CTA of neck/brain vessel will be asked if we can ask them to participate in this study. Of the ones with carotid stenosis 30% or more we will ask patients to participate in this study.

Brief summary: Primary purpose of the study is to show wether computed tomography with photon counting detector has a diagnostic image quality as good as, or better than classic computed tomography in investigations concerning stroke work-up.

Detailed description: Images of the skull/brain at the level of the inner ear/temporal bone and the level of nucleus lentiformis will be compared with the same patients routine brain done in TIA (transient ischemic attack)/stroke workup.

Images of the carotid plaque will be compared with the same patients routine CT-angiogram done in TIA/stroke workup.

Eligibility criteria: Inclusion Criteria:

* Brain exam with CT and/or CT neck/brain vessels prior to this study. Regarding neck-vessel imaging - carotid stenosis of 30% or more. Normal kidney function.

Exclusion Criteria:

* no contraindications to iodine contrast for neck-vessel imaging with contrast.

Primary outcomes:
measure: Equal or better images vs classic computed tomography.
timeFrame: During 2020
Secondary outcomes:
measure: Diagnostic information in comparison with MRI
timeFrame: During 2020
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska Institutet, Karolinska University Hospital
Study officials:
References:
Clinical trial NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
Official title: Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Biliary Tract Neoplasms
Lead sponsor: 3D Medicines
Sponsor class: INDUSTRY
First posted: 2018-03-27
Enrollment: 480
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer.

The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.


Eligibility criteria: Inclusion Criteria:

* Eighteen years and older;
* Histological or cytological diagnosis of unresectable or metastatic gallbladder cancer or cholangiocarcinoma;
* Previously untreated with systemic therapy; Subjects who developed recurrent disease \>6 months after a sort of adjuvant, neoadjuvant chemotherapy could also be eligible.
* Liver function Child-Pugh A or B;
* Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;
* Life expectancy of at least 12 weeks;
* At least one measurable lesion per RECIST 1.1;
* Adequate organ function

Exclusion Criteria:

* Specific anti-tumor treatment prior to 4 weeks;
* more than 50% liver metastasis ;
* Patient with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection etc;
* History of severe hypersensitivity reaction to any monoclonal antibody or chemistry;
* Women who are pregnant or in the period of lactation;
* Patients with an active, known or suspected autoimmune disease. Patients are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement;

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: Observed by 12 weeks after progressive disease or end of treatment
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: Observed by 6 weeks
measure: Objective response rate (ORR)
timeFrame: Observed by 6 weeks
measure: Disease control rate (DCR)
timeFrame: Observed by 6 weeks
measure: Duration of Response (DOR)
timeFrame: Observed by 6 weeks
measure: Time to progression (TTP)
timeFrame: Observed by 6 weeks
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The Chinese people's liberation army (PLA) 81hospital
state: Jiangsu
Study officials:
affiliation: The Chinese people's liberation army (PLA) 81 hospital
name: Shukui Qin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03510988: Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer
Official title: Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Newly Diagnosed Breast Cancer
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2018-04-27
Enrollment: 14
Sex: FEMALE
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single institution study enrolling women over age 25 with newly diagnosed breast cancer and for whom a breast MR has been ordered as standard of care. Subjects will undergo a hybrid dedicated Breast PET/MRI in lieu of a breast MRI alone, for evaluation of extent of disease prior to surgical and oncologic management. The study will investigate any incremental added benefit to breast MRI specificity by the addition of concurrent hybrid breast PET.

Detailed description: The study hypothesis is that the combination of Breast PET/MRI, will improve specificity and decrease the number of false positive breast biopsies recommended based on breast MRI findings.

Eligibility criteria: Inclusion Criteria:

* Women over age of 25 with newly diagnosed breast cancer and for whom a breast MR has been ordered as standard of care

Exclusion Criteria:

* Male subjects
* Women younger than 25
* Pregnant subjects
* Unable or unwilling to undergo MRI
* Previous adverse reaction to 18F-FDG
* Unwilling to undergo biopsy of MRI positive lesions

Primary outcomes:
measure: Specificity of the PET-MRI Compared to MRI Alone as Assessed by the Percentage of True Negatives Out of All Benign/Non-malignant Lesions Breast Cancer
timeFrame: 24 months
Secondary outcomes:
measure: Sensitivity, PPV (Positive Predictive Value), and NPV (Negative Predictive Value) for the Diagnosis Based on the Entire PET/MRI and MRI Alone Will be Calculated and Reported Along With the Corresponding Two-sided 90% Confidence Intervals.
timeFrame: 24 months post-intervention
measure: Average Signal to Noise Ratios (SNR) vs. IV FDG Dosages Will be Summarized in Plot Format.
timeFrame: 24 months post-intervention
measure: Number of Interval Recurrences
timeFrame: 24 months post-intervention
measure: Sensitivity in Detection of Axillary and Internal Mammary Lymph Node Metastasis Between the Hybrid Breast FDG PET/MRI vs Breast MRI Alone Will be Summarized
timeFrame: 24 months post-intervention
measure: Perceived Patient Benefit of Undergoing a Simultaneous FDG PET/MRI Will be Summarized
timeFrame: 24 months post-intervention
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Katerina Dodelzon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01997788: The Intrathecal Morphine for Nephrectomy
Official title: The Efficacy of Intrathecal Morphine in Patients Undergoing Open Nephrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Cell Carcinoma
Keywords: Injection, Spinal
Morphine
Analgesia
Patient-Controlled
Pain
Postoperative
Combined Modality Therapy
Nephrectomy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2013-11-28
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and the safety of the intrathecal morphine injection in the open nephrectomy.

Detailed description: The open nephrectomy is the treatment of choice for live donor kidney transplantation and renal cell carcinoma. The incision for the nephrectomy causes severe postoperative pain. A single dose of intrathecal morphine(ITM) has been used for the postoperative pain of prostatectomy, transurethral resection of the prostate and hepatectomy. The effect of ITM for open nephrectomy has not been studied. Therefore, this prospective, randomized study will evaluate the efficacy and safety of a single 50 mcg dose of ITM added to intravenous patient controlled analgesia(IV-PCA), comparing to IV-PCA alone.

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for the open nephrectomy

Exclusion Criteria:

* Patients with renal insufficiency
* Patients with coagulopathy
* History of any neurologic disorder
* History of recent infection in 2 weeks
* History of drug abuse
* Patients who cannot understand the usage of th intravenous patient-controlled analgesia
* Patients using opioids due to the chronic pain

Primary outcomes:
measure: The evaluation of pain at 24 hours after surgery
timeFrame: at postoperatively 24 hours
Secondary outcomes:
measure: The consumption of analgesics
timeFrame: at postoperatively 24 hours
measure: The consumption of intraoperative opioids
timeFrame: From the induction of anesthesia till the emergence of anesthesia, an expected average of 4 hours
measure: The side effects of opioids after surgery
timeFrame: During 72 hours after the end of surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University of Hospital
Study officials:
affiliation: Seoul National University of Hospital
name: Deok-Man Hong, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03405688: Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors
Official title: Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sickle Cell Disease
Sickle Cell Trait
Keywords: Sickle cell
Heterozygous
Blood donor
Lead sponsor: Brugmann University Hospital
Sponsor class: OTHER
First posted: 2018-01-23
Enrollment: 173
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown. However, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.


Eligibility criteria: Inclusion Criteria:

All patients with sickle cell disease within the CHU Brugmann and the Queen Fabiola Children's Hospital (HUDERF)

Exclusion Criteria:

None

Primary outcomes:
measure: Hemoglobin level -patient
timeFrame: 1 hour before blood transfusion
measure: Hemoglobin level -patient
timeFrame: 1 hour after blood transfusion
measure: % of 'S' type hemoglobin -patient
timeFrame: 1 hour before blood transfusion
measure: % of 'S' type hemoglobin -patient
timeFrame: 1 hour after blood transfusion
measure: Hemoglobin level - transfused blood
timeFrame: 1 hour before blood transfusion
measure: % of 'S' type hemoglobin -transfused blood
timeFrame: 1 hour before blood transfusion
measure: Transfusion yield
timeFrame: 1 hour after blood transfusion
measure: Medical complications
timeFrame: 1 month
measure: Length of stay
timeFrame: 1 month
measure: Length of stay post transfusion
timeFrame: 1 month
measure: Number of blood transfusions
timeFrame: 1 month
measure: Hospital re-admission
timeFrame: 1 month
measure: Mortality rate
timeFrame: 1 month.
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHU Brugmann
city: Brussel
country: Belgium
facility: HUDERF
Study officials:
affiliation: CHU Brugmann
name: Marie Deleers, Ph Biol
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00910988: Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Official title: A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperglycemia
Hyperlipidemia
Keywords: healthy
sedentary
men
acute effects of antipsychotic
blood sugar
insulin sensitivity
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2009-06-01
Enrollment: 46
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Primary Aim: To test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates (mg/kg/min), hepatic glucose production (glucose rate of appearance \[Ra\]), primarily muscle glucose utilization (glucose rate of disappearance \[Rd\]), and adipose tissue related free fatty acid production (glycerol rate of appearance \[Ra\]).

We hypothesize that olanzapine, but not ziprasidone, will result in acute decreases in insulin sensitivity.

Secondary Aim: To test the acute effects of olanzapine or ziprasidone on insulin signaling pathways in antipsychotic naïve healthy young men.

We hypothesize that olanzapine, but not ziprasidone, will result in acute alterations in insulin signaling.

Detailed description: See brief description

Eligibility criteria: Inclusion Criteria:

* Males aged 18-45 years
* BMI approximately ≥ 25 and \< 35
* insulin approximately ≥ 15 µU/ml or triglyceride approximately ≥ 130 mg/dl

Exclusion Criteria:

* Any DSM-IV Axis I diagnosis
* prisoners
* any serious medical disorder (i.e. metabolic diseases, type 1 or 2 diabetes mellitus, endocrine disease, coagulopathy, clinically significant anemia, acute infection)
* taking prescription medications
* non-sedentary lifestyle with \> 3 hours of exercise per week

Primary outcomes:
measure: Whole Body Insulin Sensitivity
timeFrame: approximately 3 hours
measure: Hepatic Insulin Sensitivity
timeFrame: approximately 3 hours
measure: Peripheral Insulin Sensitivity
timeFrame: approximately 3 hours
measure: Adipose Tissue Insulin Sensitivity
timeFrame: approximately 3 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine and Florida Atlantic University
name: John W Newcomer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Washington University School of Medicine
name: Ginger Nicol, MD
role: PRINCIPAL_INVESTIGATOR
References: